Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SUPLEXA cell therapy - Alloplex Biotherapeutics

Next Previous
X
Search
Drug Profile

SUPLEXA cell therapy - Alloplex Biotherapeutics

Alternative Names: SUPLEXA Therapeutic Cells

Latest Information Update: 13 Aug 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Alloplex Biotherapeutics
  • Class Antineoplastics; Cell therapies; Immunotherapies
  • Mechanism of Action Cell replacements; Immunologic cytotoxicity
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Haematological malignancies; Solid tumours

Most Recent Events

  • 23 Jul 2024 Alloplex Biotherapeutics completes a phase I trial in Haematological malignancies and Solid tumours (Late-stage disease; Metastatic disease, Second-line therapy or greater, In adults, In the elderly) in Australia (IV) (NCT05237206)
  • 31 May 2024 Adverse events and efficacy data from Phase-I trial in Haematological malignancies presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
  • 22 Aug 2023 SUPLEXA cell therapy - Alloplex Biotherapeutics is available for licensing as of 22 Aug 2023. https://alloplexbio.com/

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top